Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

FIRE, NVLS, FWRD, PWRM - Stock News! from CRWEfinance.com

crwefinancelogo2

signup3m

___

Power3 Medical Products, Inc. (OTC:PWRM)

Power3 Medical Products, Inc., a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. Power3’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. Power3’s products analyze proteins and their mutations to assess an individual’s risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. Power3 was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. Power3 was founded in 1992 and is based in The Woodlands, Texas.

How BC-SeraPro Works

BC-SeraPro is a blood serum test designed to diagnose breast cancer in individuals. The test is based on proteomic technology in which a blood serum sample drawn from a patient will monitor the concentration of each protein biomarker residing in a panel of blood serum protein biomarkers to determine if a patient has breast cancer. The biomarkers in the panel have been selected for their ability to discriminate breast cancer patients from non-cancerous patients. Power3’s statistical model evaluates the quantitative information of the protein biomarkers and automatically assigns a probability score. The probability score indicates to the physician that the patient “has cancer” or is “cancer-free”. The score reflects how strongly the patient sample fits the biostatistical model and if the patient should be recommended for further follow-up by the clinician.

Blood serum collection is a routine procedure performed by a clinician. A small sample of blood is drawn from a vein. When a blood sample is collected and stored in a tube without anticoagulant, it forms a clot after 30-60 minutes. The liquid portion remaining is the blood serum. This serum sample is then frozen and transported to the Power3 Medical CLIA certified laboratory, utilizing pre-approved carriers/delivery service, where sample preparation and analysis begins.

To learn more about PWRM visit: http://www.Power3Medical.com

*****

Sourcefire, Inc. (Nasdaq:FIRE) the creator of Snort and a leader in intelligent cybersecurity solutions, announced its partnership with Q1 Labs, a global provider of security intelligence solutions, to integrate the Sourcefire Intrusion Prevention System (NYSEARCA:IPS) with QRadar Security Information and Event Management (SIEM) delivering greater contextual awareness into network security events. With this integration, Sourcefire is providing customers with increased correlation and forensics capabilities, enabling users to more effectively identify network threats and anomalies.

Sourcefire, Inc. provides intelligent Cybersecurity solutions for information technology (NYSE:IT); environments of commercial enterprises, such as healthcare, financial services, manufacturing, energy, education, retail, and telecommunications; and federal, state, and international government organizations worldwide.

*****

Novellus Systems, Inc. (Nasdaq:NVLS) reported operating results for its fourth quarter and year ended December 31, 2010. Net sales for the fourth quarter were $384.4 million, up $17.2 million or 4.7 percent from third quarter 2010 net sales of $367.2 million, and up $140.2 million or 57.4 percent from fourth quarter 2009 net sales of $244.2 million. Net income for the fourth quarter was $81.5 million, or $0.89 per diluted share, up $5.2 million from the third quarter 2010 net income of $76.3 million, or $0.82 per diluted share, and up $46.3 million from the fourth quarter 2009 net income of $35.2 million, or $0.36 per diluted share.

Novellus Systems, Inc., together with its subsidiaries, develops, manufactures, sells, and supports equipment used in the fabrication of integrated circuits. It operates in two segments, Semiconductor Group and Industrial Applications Group.

*****

Forward Air Corp. (Nasdaq:FWRD) will release its fourth quarter 2010 earnings after the market closes on Monday, February 14, 2011 and hold a conference call to discuss those results on the following day, February 15, 2011 at 9:00 a.m. EST. The Company’s conference call will be available online on the Investor Relations portion of the Company’s website at www.forwardair.com or by dialing (800) 841-9385, passcode: 156 499 68. A replay of the conference call will be available at the company's website beginning shortly after completion of the live call.

Forward Air Corporation provides surface transportation and related logistics services to the North American deferred air freight market. The company operates in two segments, Forward Air, Inc. (Forward Air) and Forward Air Solutions, Inc. (FASI).

___

********************************************************************

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.  Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).